Tag: Ménière’s Disease



Otonomy Announces Plan to Focus on Development of Drug for Ménière’s Disease

Otonomy intends to complete the clinical development to support registration of OTIVIDEX in the United States for patients with Ménière’s disease, and will advance multiple programs for the prevention and treatment of sensorineural hearing loss, and the treatment of tinnitus.

Read More

Otonomy to Host Key Opinion Leader Meeting June 27

The meeting will feature presentations by opinion leaders Paul R. Lambert, MD, and Anthony A. Mikulec, MD, MBA, who will discuss the significant disease burden and unmet medical needs in the treatment of Ménière’s disease, review the OTIVIDEX™ Phase 2b clinical trial results, and share their clinical trial experience using OTIVIDEX.

Read More

Treatment of Ménière’s Disease and Vertigo with Intranasal Betahistine to be Developed by Auris Medical

Auris Medical will develop betahistine dihydrochloride in a spray formulation for the intranasal treatment of Ménière’s disease and vestibular vertigo. The company also announced last week that it has resumed patient enrollment in the TACTT3 Phase 3 trial of Keyzilen® (AM-101) for acute and post-acute inner ear tinnitus.

Read More